Synthetic lethal targeting of superoxide dismutase 1 selectively kills RAD54B-deficient colorectal cancer cells

Babu V Sajesh1, Melanie Bailey, Zelda Lichtensztejn

  • 1Manitoba Institute of Cell Biology and Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Manitoba, R3E 0V9, Canada.

Genetics
|September 5, 2013
PubMed

Insights

Synthetic lethality identifies SOD1 as a novel cancer drug target. Inhibiting SOD1 selectively kills RAD54B-deficient cancer cells by causing persistent DNA damage and apoptosis.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Synthetic lethality offers a strategy for targeted cancer therapy by exploiting genetic vulnerabilities.
  • Chromosome instability (CIN) is a hallmark of many cancers, presenting potential targets for synthetic lethality approaches.

Purpose of the Study:

  • To identify synthetic lethal partners of yeast CIN genes for potential cancer drug targets.
  • To validate the conserved synthetic lethal interaction between RAD54B and SOD1 in human colorectal cancer cells.

Main Methods:

  • Genome-wide synthetic lethal datasets in yeast were queried using CIN genes.
  • Hierarchical clustering identified highly connected synthetic lethal partners.
  • Mammalian cell experiments validated the RAD54B-SOD1 synthetic lethal interaction using siRNA and chemical inhibition.

Main Results:

  • A subset of synthetic lethal partners linked to colorectal cancer mutations was identified.
  • The synthetic lethal interaction between yeast rad54 and sod1 was conserved in human cells.
  • SOD1 inhibition in RAD54B-deficient cells led to increased reactive oxygen species, DNA double-strand breaks, and apoptosis.

Conclusions:

  • SOD1 is a promising candidate drug target for cancers with RAD54B deficiencies.
  • Targeting SOD1 may offer broad-spectrum therapeutic applicability in various tumor types.